share_log

Novavax | 4: Statement of changes in beneficial ownership of securities-Officer Dubovsky Filip

SEC announcement ·  Mar 11 21:43
Summary by Moomoo AI
On March 7, 2024, Novavax's President of R&D, Filip Dubovsky, completed a transaction involving the company's common stock. Dubovsky sold 9,392 shares at a price of $5.61 each, totaling $52,689.12. Prior to this sale, he exercised options to acquire 19,444 shares of Novavax common stock. Following these transactions, Dubovsky's direct holdings in Novavax amounted to 63,834 shares. The sale was executed under a transaction code indicating the payment of exercise price or tax liability by delivering or withholding securities.
On March 7, 2024, Novavax's President of R&D, Filip Dubovsky, completed a transaction involving the company's common stock. Dubovsky sold 9,392 shares at a price of $5.61 each, totaling $52,689.12. Prior to this sale, he exercised options to acquire 19,444 shares of Novavax common stock. Following these transactions, Dubovsky's direct holdings in Novavax amounted to 63,834 shares. The sale was executed under a transaction code indicating the payment of exercise price or tax liability by delivering or withholding securities.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more